Vidalista 80 mg contains tadalafil, a PDE5 inhibitor similar to other ED medications. At standard doses (5–20 mg), tadalafil has been well‑studied in clinical trials and shown to be generally safe and well‑tolerated, with common side effects like headache, dyspepsia (indigestion), back pain, and flushing typical but usually mild to moderate. Tadalafil has also been evaluated long‑term (up to 18–24 months) with no major new safety concerns in standard dosing ranges.

However, 80 mg formulations like Vidalista 80 mg are significantly higher than doses approved by major regulatory agencies (e.g., FDA/EMA) and are not standard prescriptions. Safety data indicate that higher doses increase the likelihood and severity of side effects, including drop in blood pressure (hypotension), prolonged erections (priapism), headaches, dizziness, and muscle pain.

There are also rare but serious safety signals associated with tadalafil use in general, such as non‑arteritic anterior ischemic optic neuropathy (NAION, sudden vision loss) and hearing changes, though a direct causal relationship isn’t firmly established.

Because high‑strength products carry greater risk of adverse effects, especially in men with heart, liver, or kidney conditions or those taking nitrates or alpha‑blockers, professional medical evaluation and supervision are crucial before using Vidalista 80 mg.